Fig. 5From: Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatinSelective targeting of CXCR2 reduces tumor growth in LL2 orthotopic lung cancer and subcutaneous tumor models. a, Therapy regimen of the experiment. CXCR2 inhibitor SB225002 was administered at 10 mg/kg by intraperitoneal (i.p.) injection every day, n = 6–7. b, Tumors from vehicle- and SB225002-treated groups of lung orthotopic model (upper panel) and subcutaneous tumor model (down panel) at the end point of experiment, respectively. c-d, Tumor nodules in the lung and lung weight of the orthotopic model treated with vehicle or SB225002, Data was shown as mean ± SD, n = 5. e-f, Tumor growth curves and tumor weight at the sacrifice of subcutaneous xenograft model. Data was shown as mean ± SD, n = 5. g-h, Body weight changes of the mice from orthotopic model (g) and subcutaneous xenograft model (h). Data was shown as mean ± SD, n = 5. *p < 0.05, **p < 0.01, ***p < 0.001, ns represents p>0.05Back to article page